MBX Biosciences, Inc. (MBX)
NASDAQ:MBX
Want to see MBX full AI Analyst Report?
MBX Stock Chart & Stats
$33.77
-$0.30(-2.05%)
At close: 4:00 PM EST
$33.77
-$0.30(-2.05%)
Day’s Range― - ―
52-Week Range$9.00 - $44.89
Previous CloseN/A
Volume52.29K
Average Volume (3M)478.03K
Market Cap
$1.52B
Enterprise Value$999.62M
Total Cash (Recent Filing)$373.70M
Total Debt (Recent Filing)$596.00K
Price to Earnings (P/E)―
Beta1.96
Next Earnings
May 18, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding47,510,242
10 Day Avg. Volume447,156
30 Day Avg. Volume478,026
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)3.12
Price to Sales (P/S)0.00
P/FCF Ratio-14.06
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.25K
Enterprise Value/Ebitda-10.47
Forecast
1Y Price Target
$69.20Price Target Upside104.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Lead Therapy Valuation SupportAnalyst states the clinically advanced lead therapy offers a once-weekly injectable alternative to daily hypoparathyroidism treatment, representing a clinically de‑risked asset that could provide a valuation floor and drive upside as it advances through pivotal testing.
Obesity Platform PotentialAnalyst emphasizes the peptide platform and experienced scientific leadership could enable a once-monthly incretin for obesity with infusion-like exposure and improved tolerability, potentially validating the company's prodrug technology and strengthening its position in obesity treatments.
Regulatory And Trial DesignAnalyst notes a Phase III for the lead parathyroid hormone program is planned with FDA-aligned design and a study size selected to detect normalization of urinary calcium, which could support an additional label claim and clinical differentiation.
Bears Say
Cash Burn And Financing RiskAnalyst flags a high cash burn that may necessitate additional financing and create execution risk for the company's development plan.
Phase III Replication RiskAnalyst warns there is risk the Phase III program may not reproduce earlier positive results, which would significantly weaken the investment case.
MBX Biosciences, Inc. News
MBX FAQ
What was MBX Biosciences, Inc.’s price range in the past 12 months?
MBX Biosciences, Inc. lowest stock price was $8.99 and its highest was $44.89 in the past 12 months.
What is MBX Biosciences, Inc.’s market cap?
MBX Biosciences, Inc.’s market cap is $1.52B.
When is MBX Biosciences, Inc.’s upcoming earnings report date?
MBX Biosciences, Inc.’s upcoming earnings report date is May 18, 2026 which is in 19 days.
How were MBX Biosciences, Inc.’s earnings last quarter?
MBX Biosciences, Inc. released its earnings results on Mar 23, 2026. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.605 by $0.115.
Is MBX Biosciences, Inc. overvalued?
According to Wall Street analysts MBX Biosciences, Inc.’s price is currently Undervalued.
Does MBX Biosciences, Inc. pay dividends?
MBX Biosciences, Inc. does not currently pay dividends.
What is MBX Biosciences, Inc.’s EPS estimate?
MBX Biosciences, Inc.’s EPS estimate is -0.59.
How many shares outstanding does MBX Biosciences, Inc. have?
MBX Biosciences, Inc. has 47,510,242 shares outstanding.
What happened to MBX Biosciences, Inc.’s price movement after its last earnings report?
MBX Biosciences, Inc. reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.605. Following the earnings report the stock price went down -1.883%.
Which hedge fund is a major shareholder of MBX Biosciences, Inc.?
Currently, no hedge funds are holding shares in MBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MBX Biosciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$69.20 (104.92% Upside)
$69.20 (104.92% Upside)
Blogger Sentiment
Bullish
MBX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 624.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $525.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
343.17%
12-Months-Change
Fundamentals
Return on Equity
-28.72%
Trailing 12-Months
Asset Growth
43.42%
Trailing 12-Months
Company Description
MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Stock 12 Month Forecast
Average Price Target
$69.20
▲(104.92% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Gossamer Bio
―
Nurix Therapeutics
―
Terns Pharmaceuticals
―
Tyra Bioscience
―
Ownership Overview
26.02% Insiders
10.13% Mutual Funds
2.84% Other Institutional Investors
52.73% Public Companies and
Individual Investors